Random Ramblings #1 (RR) Note 'RR' is a subset of 'DD'

New Post Public Reply Private Reply Replies (0) Message Board
joey68
Random Ramblings #1 (RR)

Note
'RR' is a subset of 'DD' (in my world) ..in case you were wondering


Just as predicted.. well, I hate using the word 'predicted' so ill say, 'just as suspected would happen', yesterdays trading wasn't deemed significant enough to be plotted on the 3 Line Break chart, leaving April 6th as still the last significant day plotted.

Anyone notice the Elder chart? Yesterdays close was a blue bar; not red. Ahhhh.. you tricky tricky candlestick chart always not showing the whole picture. We still have great cloud support for the next 25 periods. Notice the cloud has formed a green bubble. Leading span A has gone back down to the red line. It will be interesting to see how the price reacts. ive been wanting to see the price dip low enough to hit the green line; maybe it will happen in the next 2 weeks. Of course, I don't want the price to drop, but right now, things are slow and without a PR or SEC filing, the share price isn't reflecting on the actual worth of the company, so any decent news will correct major dips, so I'm not worried about it.

6 more periods to that elusive April 20th date. How will the chart react? We shall see.

My theory:
The 10Q will show sales. From where? I'm not sure. I'm trying to decide if the UK will be last to show sales and perhaps Germany is ahead of the game. If I had to guess... id say sales will come from these countries in this order (pure guess and just having some fun here):

1. Germany
1a. France
2. Italy
3. Spain
4. Saudi Arabia
5. UK
6. Africa
7. US

This isn't taking into consideration smaller countries in the EMEA. But seeing we had sales last year, I don't really see why we wouldn't have sales in this 10Q. Remember, SCIE sells the forceps in a box as a set. If there were sales last year, and whoever bought the stuff needs more forceps.. theyre going to have to buy them; and these purchase should (in theory) show up in this 10Q.

China is somewhere in that list, but I have no clue when sales would show. I wrote that crazy long post a while back about how SCIE is in touch with China (its all in post #305 if youre interested)

This is a quote from that post:

Quote:
Conclusion:
OneMedMarket, a company based in New York, owns its subsidiary OneMedChina. OneMedMarket created OneMedChina as a way to introduce Western technology to China. And JUST like SCIE's PR said a few years ago that they wanted to expand to China.. guess what.. it's already in the works.

And the people behind Spectra Science either approached OneMedmarket for help, or OneMedMarket found out about SCIE and asked if they wanted their services. Apparently, either way, SCIE is using the services of OneMedmarket which does this..


Quote:
We will use the network created by China Forum (which SCIE was at) over the past five years to facilitate joint ventures, distribution agreements (which SCIE said they were going to do) and direct investment in promising companies with a strong potential in China


And the conclusion to all this; this isn't some dead end, 12 year old press release. This happened LAST MONTH which means Spectra Science is both ACTIVELY working on getting their product sold in China AND Spectra Science is ACTIVELY networking around the world. Which means, MORE PR's, MORE SEC filings, MORE potential!


Of course, coming back to reality.. no sales is also a possibility as well, but I'm guessing sales will show up in the 10Q.

One thing I don't like is SCIE's website. Come on now, update it would ya!? The bottom shows 'Spectra Science News', but it has news from 2014. I don't get how the person in charge of this stuff doesn't realize this; not just with SCIE, but any company. Even billion dollar companies have outdated information. Whatever the case may be, their website isn't a deal breaker, but it sure would be nice for whomever is in charge of the site to simply UPDATE THE NEWS ON THE MAIN WEBPAGE. See? I'm not afraid to point out the flaws in my investments.

I have seen a small number of companies not bother to update their website because they have things planned for an eventual buyout and aren't wasting time, energy, or money on updating their site. Buuuuut.... with SCIE? A buyout? Right now?? They don't have an EV of $10 million yet. Any buyout wouldn't be until around 2018-2020 in my opinion. wow, this post turned into a ramble. I guess not every post of mine can be mind blowing DD, right?

I definitely believe, for the short term, the price is going to hover around these levels until news comes out. Its kind of like Olympic swimmers itching for the starting pistol to go off. The investors are the swimmers. There's probably hundreds of people itching to buy shares; but only at a higher price of around .05, .25, and .50 cents. They want confirmation that this company is going somewhere before jumping in the pool.

If SCIE takes off like I think it will, it will be interesting in a couple of years to see if anyone still has any .0007 - .0009 shares. I know of one stock which is now at around $12 where a select few are still holding on to their .original 30 cent purchase. That's crazy.

Ok, so this post turned more into a diary entry. Perhaps I should have started it with, "Dear Diary.."

SpectraSCIENCE Inc. (SCIE) Stock Research Links

SCIE Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sarepta Under Scrutiny: KSF's Investigation Deepens

Updated Category News Views 3

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Continue Reading
Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Updated Category News Views 4

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 3

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
Postal Service Defends New Rule Amid Speculation

Updated Category News Views 3

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Continue Reading
Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 6

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
TrailBlazer Magazine Snags a Tribune for In-House Design

Updated Category News Views 4

Who Knew? Design Awards Aren't Just for Pretty Pictures TrailBlazer Magazine gets a pat on the back from GDUSA's 2026 Inhouse Design Awards, a nod to top-notch design work. With over 4,000 entries across the board, getting into the top 10 percent is like finding a steakhouse with zero line on a Friday night. Not exactly common, right? Design Worth Cheering For The winning...

Continue Reading
MMRO Achieves URAC AI Accreditation, Ensures Compliance

Updated Category News Views 4

A Milestone in Healthcare AI: MMRO's New Accreditation When AI in healthcare gets an official nod from the big guys like URAC, it's a significant moment. We're talking about Managed Medical Review Organization, Inc. (MMRO), a firm that's just earned the URAC Artificial Intelligence in Health Care Accreditation. Now, this isn't just some rubber stamp; it's a testament to...

Continue Reading
Dimerix Locks Down A$34M Loan: No Shareholder Dilution

Updated Category News Views 2

Dimerix Grabs Non-Dilutive Funds amid Kidney Trials Here we go with Dimerix's latest move, folks. They roped in A$34 million through a cozy get-together with lenders from Australia and the U.S. What's the kicker? This cash won't touch shareholder equity. So, breathe easy, investors. It's a rare feat to pull off non-dilutive funds these days, especially in the biopharma...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming the Narcolepsy Market: Innovations Ahead

Updated Category News Views 166

The Evolving Landscape of the Narcolepsy Market The narcolepsy market is undergoing significant changes as it shifts from merely managing symptoms to developing targeted therapies that tackle the root causes of the disorder. Traditionally, treatments focused on alleviating symptoms, but advancements now emphasize addressing the underlying neurochemical issues, primarily...

Continue Reading
UBS Analysts Share Insights on China Stocks Strategies

Updated Category News Views 242

UBS Analysts Offer Insights on China's Equity Market In a recent discussion, UBS strategists have expressed a level of caution regarding China's equity market as they look into the evolving landscape of 2025. It's noted that local A-share investors appear hesitant to seize buying opportunities, influenced by a myriad of factors that create uncertainty in the market....

Continue Reading
Palisade Bio's Special Meeting Cancellation: What You Need to Know

Updated Category News Views 133

Palisade Bio Cancels Special Meeting of Stockholders Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company making strides in developing innovative treatments for autoimmune, inflammatory, and fibrotic diseases. Recently, the company announced an important decision regarding its special meeting of stockholders. The special meeting, originally...

Continue Reading
Vivendi Reports Impressive 4.5% Revenue Growth in 2024

Updated Category News Views 123

Remarkable Revenue Growth for Vivendi Vivendi has announced an impressive increase in its revenues for the first nine months of 2024, emphasizing strong growth across its core business sectors. The company reported a revenue increase of 4.5% at constant currency and perimeter, compared to the same period in the previous year. This growth showcases the resilience and...

Continue Reading
Revolution in Home Renovation Arrives with Spray-Net Franchise

Updated Category News Views 226

Fresh Approach to Home Makeovers Home remodeling isn’t just about slapping on a new coat of paint anymore. In February 2026, Spray-Net is gearing up to launch in Allen, Texas, shaking things up in the renovation game. This venture represents a leap forward—not only for franchise growth but for homeowners who are sick and tired of traditional, drawn-out renovations....

Continue Reading